S ince the first percutaneous coronary intervention (PCI) was performed 35 years ago, there have been profound and sustained evolutions in catheter-based revascularization that have shifted the treatment of patients with coronary artery disease (CAD) largely away from an initial pharmacological approach to one that has increasingly emphasized an anatomically driven management strategy. Because there are abundant clinical trial data that support the benefit of urgent/ emergent PCI in patients with ST-segment-elevation myocardial infarction or non-ST-segment-elevation acute coronary syndromes (ACS) in reducing death or myocardial infarction (MI), 1a-6 there has been an expanding use of PCI and physician embracement of coronary stenting that has revolutionized patient management and clinical outcomes in these high-risk patients.
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Less well recognized and appreciated over the past 2 decades has been the concomitant evolution and refinement in medical therapy, which has become increasingly robust by contemporary standards and now includes the routine use of evidence-based "disease-modifying" secondary prevention therapies (eg, aspirin, thienopyridines, statins, inhibitors of the renin-angiotensin system, and ␤-blockers for post-MI patients), all of which have been shown in placebocontrolled, randomized controlled trials (RCTs) to reduce death and MI in CAD patients. Additionally, important treatments directed primarily toward anginal symptoms and relief of ischemia (eg, ␤-blockers for angina, calcium channel blockers, long-acting nitrates, and ranolazine) are widely used clinically. When these proven therapies are combined with lifestyle interventions (a heart-healthy diet and weight loss/maintenance, smoking cessation, and regular physical exercise), the aggregation of these complementary and addi-tive management approaches is frequently referred to as optimal medical therapy (OMT). 7 It is against this therapeutic backdrop that clinicians frequently are faced with discordant evidence from clinical trials that complicate decision making for patients with symptomatic CAD. We universally accept the fact that total or subtotal coronary occlusion after plaque rupture or fissuring in ACS patients is a cardiovascular emergency that cannot be optimally managed medically. By contrast, several RCTs such as the Clinical Outcomes Utilizing Revascularization and Aggressive druG Evaluation (COURAGE) Trial, 7 Bypass Angioplasty Revascularization 2 Diabetes Trial (BARI-2D), 8 and Japan Stable Angina Pectoris (JSAP) study, 9 as well as numerous meta-analyses of these RCTs, 10 -14 including a very recent one of 8 stent trials in the era of modern medical therapy, 15 have all failed to demonstrate any incremental clinical benefit for PCI above and beyond OMT for the reduction of death or nonfatal MI, hospitalization for ACS, need for unplanned revascularization, and a durable, sustained effect on angina relief-findings quite in contrast to those achieved with PCI in acute MI or ACS patients. 1a-6 Yet, although data derived from RCTs are frequently cited as the putative "gold standard" of high-quality scientific evidence that underlies our professional society treatment guidelines, there are nonetheless well-recognized shortcomings that impact the degree to which such data can be generalized more broadly to the universe of patients who are treated in the "real-world" setting of routine clinical practice. Thus, an equally important source of scientific evidence derives from observational studies, prospective registries, and longitudinal clinical databases. Among the most important of these in CAD management over the past 15 years has been that of the New York State Cardiac Advisory Board's Cardiac Diagnostic Catheterization Database and PCI Registry. Dr Hannan and his coworkers have made significant and sustained contributions to our collective understanding of the real-world implications of myocardial revascularization in clinical practice, and once again, in this issue of Circulation, this group of investigators has reported on the comparative outcomes for patients who do and do not undergo PCI for stable CAD in New York State. 16 Because there is a paucity of data regarding what treatments patients receive after undergoing diagnostic coronary angiography for stable CAD, Hannan et al 16 examined the 4-year clinical outcomes between patients who received routine medical treatment (RMT) with or without PCI between 2003 and 2008. Overall, a total of 9586 patients were followed up prospectively in this registry, of whom 8486 (or 89%) received PCI, 2% underwent bypass surgery, and only 11% received medical therapy. However, the principal focus of this analysis involved a cohort of patients who were propensity matched for 20 potential factors that could have a bearing on both the treatment received (PCI plus RMT versus RMT alone) and the outcomes resulting from treatment. Outcomes of interest for this study were the composite of death or MI, death alone, MI alone, and the rate of subsequent revascularization during a median 2.87-year follow-up. As noted above, because so few patients (nϭ1100) received RMT alone, the propensity matching comprised only 933 matched pairs of patients (nϭ1866).
The main study findings revealed that compared with those who received RMT alone, patients who received PCI plus RMT had a significantly lower rate of death or MI (16.5% versus 21.2%, Pϭ0.003), mortality (10.2% versus 14.5%, Pϭ0.02), MI (8.0% versus 11.3%, Pϭ0.007), and subsequent revascularization (24.1% versus 29.1%, Pϭ0.005). 16 Adjusted hazard ratios representing the relative outcomes across the entire follow-up period (up to 4 years) also favored the PCI-plus-RMT versus RMT-only group for both death/MI and death alone. The rate of PCI for stable CAD in this analysis before COURAGE (2003-2007) was 88.4% and was virtually identical (88.7%) after COURAGE (2008). Of note, there were no differences in comparative outcomes for patients Ͻ65 years of age or for patients who underwent PCI for single-vessel CAD between the PCI-plus-RMT and RMTalone groups.
Thus, when physicians confront the decision of how best to treat patients with symptomatic CAD, they frequently consider whether the initial management approach should be OMT alone or OMT in addition to coronary revascularization-generally PCI in the vast majority of patients for whom revascularization would be considered. In such a situation, should physicians be guided more by the findings derived from multiple RCTs and meta-analyses of these studies, or should they rely instead on the findings from observational studies and prospective registries? How should the discerning, practicing physician make sense of what appear to be diametrically opposite findings and conclusions regarding PCI for stable CAD from RCTs like COURAGE and BARI-2D (along with some 6 meta-analyses) and the data from observational studies like the current New York State Registry report? Are there important clues that might represent insights into how these data should be interpreted, and, as will be examined, is it possible that the findings from the present population-based study might not really be as apparently positive for PCI as they would at first appear?
The important observations from this analysis can be summarized as follows:
• As the authors acknowledge, there were significant differences in many important baseline characteristics between the PCI-plus-RMT and RMT-alone groups that no amount of propensity matching could completely correct or resolve. The RMT-treated patients were older, generally sicker, and had more comorbidities (higher rates of heart failure, left ventricular dysfunction, prior MI, peripheral vascular disease, renal failure, and prior coronary artery bypass graft surgery). • Unmeasured factors such as coronary lesion characteristics, bleeding risks, noncardiac comorbidities, differential rates of medication usage, the highly disproportionate percentage of patients who underwent PCI (Ϸ90%) versus RMT alone (11%), and uncertainties as to what led to referral for PCI or RMT create significant confounding and selection bias that could seriously skew the results in favor of PCI. • The small cohort of 933 matched pairs represented only 20% of the total population undergoing diagnostic coronary angiography, and as noted above, the fact that only Ϸ10% of patients received RMT alone raises serious concerns about the validity of the data and the degree to which these highly selected results can be generalized to the totality of CAD patients in the "real world." • Although the median follow-up for the propensity-matched cohort was 2.87 years, the statistical comparisons for outcomes data were based on 4-year event rates. This methodological inconsistency is not explained adequately. • Most importantly, RMT is never defined in the present study. In fact, the authors acknowledge that "the nature of the medical therapy provided to the RMT patients in [their] study is completely unknown, and undoubtedly many RMT patients received nonoptimal treatment." • The authors propose that the 2 possible reasons why RMT outcome rates were higher than in COURAGE are that the New York State RMT population was significantly less selected (and therefore at a higher risk) or because "patients had RMT instead of OMT." A frequent, but erroneous, criticism of the COURAGE trial 7 has created a misperception that these patients were "low risk" or that higher-risk patients were systematically excluded. The accompanying younger and less likely to be female, but they had higher rates of prior MI, renal failure, and significantly more extensive angiographic multivessel CAD. In short, it is highly unlikely that any differences in clinical outcomes between these 2 studies could be explained by the continued nonfactual assertions that COURAGE patients were a "highly select population" and that the "lower mortality rate in COURAGE" occurred because "many high-risk patents were excluded." • It is unclear why the rate for PCI in stable CAD in New York State was so remarkably high, at Ϸ90%. Given the absence of evidence-based data in support of PCI clinical benefit, both before and after COURAGE, one would have anticipated a greater degree of equipoise in the choice of treatment for this population for nonacute CAD patients with chronic angina, perhaps with rates of initial PCI that would be in the 50% to 60% range. These data are troubling and suggest that decision making in such an important population of patients is not in conformity with existing clinical practice guidelines. • It is particularly interesting that Hannan and coworkers 16 were unable to demonstrate that patients who received PCI plus RMT had better clinical outcomes than those who received RMT alone for 2 common and important subsets: patients Ͻ65 years of age and those who had angiographic single-vessel CAD. A recent assessment of the American College of Cardiology National Cardiovascular Data Registry revealed that among the 405 824 patients who underwent elective PCI for stable ischemic heart disease in the United States between July 1, 2009, and September 30, 2011, 43% were Ͻ65 years old, and 46% underwent PCI for single-vessel CAD. 17 Perhaps the findings of Hannan et al 16 should guide physician decision making as to who would (or would not) benefit and, as an important corollary, who should (or should not) undergo PCI for stable CAD and chronic angina. • Lastly, the authors highlight that several other studies have shown that medication adherence is generally poor, and many other studies have shown that adherence strongly affects outcomes. They allege that "although OMT is as effective as PCI/OMT for patients with stable CAD in a tightly controlled trial with excellent adherence, different results might occur in real-world situations." Most certainly, this could be true, but if no attempt was even made to initiate or quantify OMT, as in the present study, can one infer from this that it is not worth even attempting or achieving? If the bar to initiate OMT is set so low, and the physician motivation and commitment to support and achieve OMT is so limited and superficial, is it surprising that the attitude or "message" then becomes, "It's much easier to just do (and advocate for) PCI," and by contrast, just "too hard" to achieve OMT, in spite of what the compelling scientific evidence tells us? In other words, for medical therapy, has "the perfect become the enemy of the good?"
In the final analysis, how can clinicians interpret the findings of the present study in the context of trials like COURAGE and BARI-2D, in which guideline-directed medical therapy (or OMT) was the operant comparator with PCI? In the setting of such absent information about the extent and magnitude of medical therapy, do these data really inform clinical practice? Clearly, RMT does not equal OMT. From the present study, should we conclude that clinical outcomes are significantly better than medical therapy when we do not even know what constituted medical therapy in this nonrandomized comparison? Do we infer from these data that because almost 90% of stable CAD patients with angina underwent PCI, this is a defendable, evidence-based therapeutic approach? Is it a fair criticism that because high rates of adherence to treatment targets with OMT were achieved in RCTs, 7, 8 we should dismiss or diminish the importance of these therapeutic goals in routine clinical practice and, by inference, opt for the easier management approach and perceived "quicker fix" of PCI?
Although during the 5 years since COURAGE was originally published, 7 some progress and traction in the clinical practice arena has been realized, the unfortunate reality is that neither this study nor BARI-2D have been real "gamechangers." Too few CAD patients are being managed medically when this approach should be undertaken, and too many patients are being deprived of an "OMT-first" treatment paradigm when this would be both an evidence-based and clinically appropriate approach. 18 In a 2011 comparison of OMT usage before and after COURAGE by Borden et al, 19 very little difference was seen in physician treatment patterns, which suggests that either we are in denial that OMT should be viewed as the foundation for all subsequent CAD therapies or there is an unacceptably sizable blind spot in how we view the importance of OMT through the prism of a PCI-first treatment lens.
This controversy is unlikely to end until more definitive data emerge from clinical trials. The FAME-II trial (Fraction Flow Reserve-Guided Percutaneous Coronary Intervention Plus Optimal Medical Treatment Versus Optimal Medical Treatment Alone in Patients With Stable Coronary Artery Disease) was recently terminated because in patients randomized to PCI that was guided by fractional flow reserve compared with medical therapy alone without revascularization, there was a significantly lower rate of hospitalization for ACS and subsequent unplanned revascularization (FAME-II Trial Investigators, personal communication, March 2012).
Although not yet published, this trial is very likely to accelerate the use of PCI as an anatomic treatment that is further refined by an invasive physiological tool to guide its more selective use. Yet FAME-II was not designed to assess whether a fractional flow reserve-guided strategy versus OMT would reduce prognostically important ischemia subtending stenotic coronary segments, and as yet, we have no information about whether death or MI was favorably altered by this approach versus OMT alone. By contrast, the National Heart, Lung, and Blood Institute-funded International Study of Comparative Health Effectiveness with Medical and Invasive Approaches (ISCHEMIA) Trial, slated to begin enrollment in mid-2012, will address prospectively, in 8000 highrisk patients, the critical question of whether patients with moderate to severe myocardial ischemia who receive optimal myocardial revascularization combined with OMT will have a lower rate of long-term cardiovascular death or MI than those treated with OMT alone (ISCHEMIA Trial Investigators, personal communication, March 2012).
In summary, until the results of these newer trials are known, we must base treatment decisions in stable CAD patients with chronic angina on the best available evidence. In that context, we need to weigh and integrate all the current scientific information-from RCTs, meta-analyses, and observational studies-in an attempt to define and individualize the best treatment for stable CAD patients. Yet in so doing, we should not extrapolate the potential life-saving benefits of PCI in ACS patients to the broad population of stable CAD and chronic angina patients in whom PCI has not been shown to be superior to OMT and lifestyle intervention. Embracing optimal medical therapy in a PCI-first practice culture takes
